Patient #100 randomized in Empire Prevent Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial. Collaboration between Research Unit of Cardiology, OUH and Herlev og Gentofte hosp afd for hjertesygdomme.

Empire Prevent 🩵🩷 includes patients in Odense Research Unit of Cardiology, OUH and Copenhagen Herlev og Gentofte hosp afd for hjertesygdomme. We greatly appreciate our collaboration with Steno Diabetes Center Odense and RigsHeart 🫀🚨 🩵🩷

🩵🩷Empire Prevent on track! 🩵🩷 58% of target population enrolled at @CardReseachOUH & Herlev og Gentofte hosp afd for hjertesygdomme Collaboration with Steno Diabetes Center Odense & RigsHeart 🫀🚨

🩷🩵First patient follow-up at Odense University Hospital Research Unit of Cardiology, OUH ☑️🚴‍♀️🫀💊 Empire Prevent Camilla Fuchs Andersen morten schou Julie Hempel RigsHeart 🫀🚨 Steno Diabetes Center Odense Herlev og Gentofte hosp afd for hjertesygdomme

The Empire Prevent trial program marks the first step towards elucidating the potential of SGLT2 inhibition for HF prevention 🫀🫀 Further reading: pubmed.ncbi.nlm.nih.gov/38365073/ Research Unit of Cardiology, OUH Herlev og Gentofte hosp afd for hjertesygdomme RigsHeart 🫀🚨 Julie Hempel Camilla Fuchs Andersen morten schou